N04BA03 • levodopa + carbidopa + entacapone • Nervous system | Dopaminergic agents | Dopa and dopa derivatives
Levodopa + Carbidopa + Entacapone is a combination medication used in the treatment of Parkinson's disease, particularly in patients experiencing motor fluctuations ('on-off' phenomena) associated with levodopa therapy. This combination enhances treatment efficacy and prolongs the duration of levodopa's action.
- Levodopa is a precursor of dopamine, which helps compensate for the dopamine deficiency in the brain.
- Carbidopa is a peripheral decarboxylase inhibitor that prevents levodopa from being converted into dopamine outside the brain, reducing side effects such as nausea.
- Entacapone is a COMT (catechol-O-methyltransferase) inhibitor that slows the breakdown of levodopa, extending its effect in the brain.
This combination is effective in alleviating symptoms such as tremors, muscle rigidity, bradykinesia (slowness of movement), and motor fluctuations. It is important to take the medication as prescribed by a doctor, with the dosage gradually adjusted to minimize side effects.
Side effects may include nausea, diarrhea, dizziness, drowsiness, urine discoloration (brown-orange), and, in rare cases, hallucinations or compulsive behaviors. Regular monitoring is essential to adjust the treatment based on the progression of the disease.
Substance: levodopa + carbidopa + entacapone
Date of last drug list: 16-08-2017
Commercial code: W63557006
Concentration: 150mg / 37.5mg / 200mg
Pharmaceutical form: film-coated tablets
Quantity: 100
Product type: generic
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).